NCT07353502Recruiting
miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction
Effects of miR-342-5p/AnkG Pathway-Mediated Axon Initial Segment Filtering Injury on Early Synaptic Dysfunction in Alzheimer's Disease and Its Clinical Applications
Source: ClinicalTrials.gov · Last updated 20 Jan 2026
Brief summary (registry, in English)
Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities. Current research has found that in the early stages of the disease, synaptic connections between brain nerve cells become abnormal, but the specific cause is still unclear. Investigators' previous research discovered that in the brains of diseased mice, certain special substances (the miR 342 5p/AnkG-mediated pathway) might be related to this abnormality, and these substances can be detected in both blood and cerebrospinal fluid. Therefore, investigators want to further explore the specific mechanisms of abnormal nerve cell connections, seek biomarkers for early detection of the disease, and provide new ideas for early diagnosis in the future.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 17 Sept 2025
- Start date
- Jun 2025
- Primary completion date
- Mar 2026
- Lead sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Diseases
- Alzheimer disease
- NCT number
- NCT07353502
What you commit to
- Study type: Interventional
- Planned participants: 40
- From Jun 2025 to the primary completion date, Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous traumatic brain injury
Other illness
- Dementia or cognitive impairment caused by other diseases
- History of substance abuse
- Patients with comorbid depression, schizophrenia, or severe diseases of the cardiovascular, hepatic, renal, or hematological systems
- Other conditions unsuitable for inclusion
Other
- Progressive primary aphasia
- Impaired consciousness and inability to cooperate
Who the study is looking for
- Meet the diagnostic criteria for "probable AD dementia" established by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
- MMSE score between 0-23 points, Clinical Dementia Rating (CDR) score ≥0.5 points, Hachinski Ischemic Score \<4 points
- Brain MRI showing bilateral temporal lobe and hippocampal atrophy
- Age ≥50 years
- Healthy subjects with age matched to the AD group
- Normal cognitive function and good activities of daily living
- No dementia patients among first-degree relatives
- Negative brain MRI and neurological examination
Age in the registry: 50 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Fourth Affiliated Hospital of Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Yiwu | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.